REVEAL Study Results Reaffirms Importance of Cholesterol and Heart Disease
The National Lipid Association (NLA) welcomes the results of the REVEAL trial which demonstrated that reductions in cholesterol levels with anacetrapib were associated with a reduction in cardiovascular events. Specifically, cholesterol drug anacetrapib produced reductions in low density lipoprotein (LDL) cholesterol levels, non-high density lipoprotein (non-HDL) cholesterol levels, lipoprotein(a) levels and a profound increase in high density lipoprotein (HDL) cholesterol levels. These favorable lipid changes were associated with a significant reduction in cardiovascular events.
Anacetrapib is a member of a class of drugs called cholesteryl ester transfer protein (CEPT) inhibitors. The main action of CETP inhibitors is to inhibit the transfer of cholesterol from different cholesterol carrying particles. Prior to this study, other similar types of drugs did demonstrate improvements in cholesterol levels. However, despite these favorable cholesterol effects, at least 3 previous investigational CETP inhibitors did not demonstrate reductions in cardiovascular events.
Safety issues were also reported in the trial, included slightly higher blood pressure, slightly lower glomerular filtration rate (GFR) and lower rates of incidence of new-onset diabetes in the patients taking anacetrapib vs. placebo. In addition, as had been previously reported, accumulation of anacetrapib in adipose tissue was noted.
A link to the article in the New England Journal of Medicine can be found here.